Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBIT Margin (2020 - 2025)

Historic EBIT Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 2.78%.

  • GeneDx Holdings' EBIT Margin rose 73400.0% to 2.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.48%, marking a year-over-year increase of 240600.0%. This contributed to the annual value of 7.6% for FY2024, which is 815500.0% up from last year.
  • Latest data reveals that GeneDx Holdings reported EBIT Margin of 2.78% as of Q3 2025, which was up 73400.0% from 8.73% recorded in Q2 2025.
  • GeneDx Holdings' EBIT Margin's 5-year high stood at 9.21% during Q4 2024, with a 5-year trough of 529.56% in Q4 2022.
  • For the 5-year period, GeneDx Holdings' EBIT Margin averaged around 129.99%, with its median value being 96.67% (2021).
  • Per our database at Business Quant, GeneDx Holdings' EBIT Margin plummeted by -3530200bps in 2022 and then soared by 4848900bps in 2023.
  • Over the past 5 years, GeneDx Holdings' EBIT Margin (Quarter) stood at 200.31% in 2021, then plummeted by -164bps to 529.56% in 2022, then surged by 92bps to 44.66% in 2023, then surged by 121bps to 9.21% in 2024, then crashed by -130bps to 2.78% in 2025.
  • Its EBIT Margin stands at 2.78% for Q3 2025, versus 8.73% for Q2 2025 and 5.22% for Q1 2025.